8-K: Quantum-Si Reports Second Quarter 2024 Results, Launches New Sequencing Kit and Appoints New Chairman

Quantum-Si announced its second quarter 2024 financial results, the launch of a new sequencing kit, and the appointment of a new independent Chairman of the Board.

Summary

• Quantum-Si reported revenue of $622,000 for the second quarter of 2024, with a gross profit of $354,000 and a gross margin of 57%.
• For the first six months of 2024, the company's revenue was $1.1 million, with a gross profit of $623,000 and a gross margin of 57%.
• Total operating expenses for the second quarter were $26.8 million, while adjusted operating expenses were $24.4 million.
• The company's net loss for the second quarter was $23.1 million, and adjusted EBITDA was negative $22.6 million.
• As of June 30, 2024, Quantum-Si had $218.1 million in cash, cash equivalents, and marketable securities.
• The company reaffirmed its full-year 2024 revenue guidance of $3.7 to $4.2 million and expects total cash usage to be less than $100 million.
• Quantum-Si launched its version 3 sequencing kit and expects to launch two additional kits by the end of 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is still operating at a loss, the launch of new products, the appointment of a new chairman, and the reaffirmation of financial guidance are positive signs. However, the low revenue and ongoing losses temper the overall sentiment.

Positives

• The company's gross margin was a solid 57% for both the second quarter and the first six months of 2024.
• The launch of the version 3 sequencing kit is a positive step in the company's technology roadmap.
• The appointment of Chuck Kummeth as independent Chairman brings significant industry experience to the board.
• The company has reduced operating expenses while still funding the commercial launch of its Platinum instrument.
• The company has a cash runway into 2026 based on current cash reserves.

Negatives

• The company reported a net loss of $23.1 million for the second quarter of 2024.
• Adjusted EBITDA was negative $22.6 million for the second quarter of 2024.
• The company's revenue of $622,000 is still relatively low for a commercial stage company.

Risks

• The company's ability to achieve its revenue guidance is subject to market adoption of its products.
• The company's financial performance is dependent on its ability to manage operating expenses.
• The company faces competition from other companies in the proteomics market.
• The company's future success depends on its ability to develop and commercialize new products.
• The company's cash runway is dependent on its ability to manage cash usage.

Future Outlook

The company reaffirms its full year 2024 revenue guidance of $3.7 to $4.2 million and expects total cash usage to be less than $100 million. The company also maintains the expectation that the balance in cash and cash equivalents and investments in marketable securities of $218.1 million as of June 30, 2024 will provide a runway into 2026.

Management Comments

• Jeff Hawkins, President and CEO, stated that he is pleased with the progress made on the commercial ramp up of Platinum during the second quarter.
• Jeff Hawkins noted strong customer interest in the unique capabilities of Platinum.
• Jeff Hawkins mentioned that the company is in the early stages of penetrating a large market opportunity in proteomics.
• Jeff Hawkins highlighted the launch of the version 3 sequencing kit and the expected launch of two additional kits by the end of 2024.
• Jeff Hawkins stated that the company remains laser-focused on delivering a compelling technology roadmap of enhancements to its hardware, software and chemistries.

Industry Context

This announcement comes as the proteomics field is gaining increasing attention, with researchers seeking a deeper understanding of protein sequences. Quantum-Si is positioning itself as a leader in this space with its unique technology and product launches. The company's focus on innovation and commercialization is aligned with the broader industry trend of advancing drug discovery and diagnostics through proteomics.

Comparison to Industry Standards

• Quantum-Si's revenue of $622,000 in Q2 2024 is relatively low compared to established life science tools companies like Bio-Techne and Thermo Fisher Scientific, which have quarterly revenues in the hundreds of millions or billions.
• The gross margin of 57% is a positive sign, but it is important to note that this is a variable metric in the early stages of commercialization.
• The company's adjusted EBITDA of negative $22.6 million is typical for a growth-stage company investing heavily in R&D and commercialization.
• Companies like Pacific Biosciences and Oxford Nanopore, which are also in the sequencing space, have similar challenges in achieving profitability in their early stages.
• Quantum-Si's cash runway into 2026 is a positive sign, but it will need to demonstrate significant revenue growth to become self-sustaining.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the product launches and reaffirmed guidance, but concerned about the ongoing losses.
• Employees may be motivated by the company's progress and growth, but also aware of the financial challenges.
• Customers will benefit from the new products and technologies, which could lead to increased adoption.
• Suppliers may see increased demand for their products as the company scales up its operations.
• Creditors will be monitoring the company's financial performance and cash runway.

Next Steps

• The company expects to launch a version 2 library prep kit and a barcoding application specific library prep kit by the end of 2024.
• The company will continue to focus on the commercial ramp up of its Platinum instrument.
• The company will continue to deliver enhancements to its hardware, software and chemistries.

Key Dates

Keywords

protein sequencing, proteomics, financial results, sequencing kit, commercial launch, biotechnology, life sciences, Platinum instrument, operating expenses, revenue